On the other hand, cancers in which over-expression of Jag1, Jag2, and DLL1 are associated with poor survival, such as prostate [60] and breast [61]–[63] carcinomas, CNS tumors [57], and multiple myeloma [62], may be tractable targets. Here, JAG2 is linked to plasma cell myeloma.